[Adrenal function in chronic myeloid leukemia]

Area of Science:

• Endocrinology
• Hematology
• Pharmacology

Context:

• Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
• Busulphan is an alkylating agent used in CML treatment.
• Adrenal function assessment is crucial for patients undergoing long-term therapy.

Purpose:

• To evaluate adrenal cortical and medullary function in CML patients treated with Busulphan.
• To determine if CML or Busulphan therapy impacts adrenal function.
• To investigate adrenal reserve in patients with CML, including those in blastic crisis.

Summary:

• Adrenocortical function was assessed via plasma 11-hydroxysteroids (11-OHCS) and urinary 17-hydroxysteroids (17-OHCS).
• Adrenomedullary function was evaluated by measuring urinary 24-hour VMA levels.
• Most patients exhibited normal adrenal function markers; elevated levels were noted in some, particularly those with blastic crisis, suggesting preserved adrenal reserve.

Impact:

• Findings indicate that neither CML nor Busulphan treatment significantly impairs adrenal function.
• The study suggests that adrenal reserve is maintained in CML patients, even during disease progression.
• Further research into Busulphan's potential direct effects on melanin metabolism is warranted.